Sign In
Buy HALO
$69.82
+3.54 (+5.34%)
At Close: Jun 03, 2026
Halozyme Therapeutics (HALO) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
10:21am, Wednesday, 14'th Feb 2024
Evaluate the expected performance of Halozyme Therapeutics (HALO) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of i
Halozyme Therapeutics (HALO) is a Top-Ranked Growth Stock: Should You Buy?
10:46am, Friday, 26'th Jan 2024
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
3 Biotech Stocks to Sell in January Before They Crash and Burn
05:29pm, Thursday, 25'th Jan 2024
The biotech segment is one of the most potent, boasting an impressive Compounding Annual Growth Rate (CAGR) of 13.96% until 2030. However, investing in biotech stocks also bears immense risk, as compa
Can Halozyme Therapeutics (HALO) Keep the Earnings Surprise Streak Alive?
01:11pm, Wednesday, 24'th Jan 2024
Halozyme Therapeutics (HALO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term
10:44am, Monday, 22'nd Jan 2024
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Halozyme Therapeutics (HALO) Surges 5.6%: Is This an Indication of Further Gains?
05:16am, Wednesday, 17'th Jan 2024
Halozyme Therapeutics (HALO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the
Here's Why Halozyme Therapeutics (HALO) is a Strong Growth Stock
11:19am, Wednesday, 10'th Jan 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
3 Reasons Growth Investors Will Love Halozyme Therapeutics (HALO)
02:17pm, Thursday, 14'th Dec 2023
Halozyme Therapeutics (HALO) possesses solid growth attributes, which could help it handily outperform the market.
Here's Why Halozyme Therapeutics (HALO) is a Strong Value Stock
11:18am, Tuesday, 05'th Dec 2023
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Here is Why Growth Investors Should Buy Halozyme Therapeutics (HALO) Now
02:17pm, Monday, 20'th Nov 2023
Halozyme Therapeutics (HALO) could produce exceptional returns because of its solid growth attributes.
Halozyme Q3: Navigating The Ups And Downs Of Its Innovative Pathway
08:26pm, Wednesday, 15'th Nov 2023
Halozyme's Q3 2023 earnings showed robust performance, with a 41% YoY increase in product sales and a 15% YoY growth in royalty revenue. The company's strategic moves, including a $250M share repurcha
7 Underappreciated Biotech Stocks to Pick Up on the Cheap
10:01pm, Thursday, 09'th Nov 2023
Amid some rising questions for the economy, value-seeking investors may want to consider underappreciated biotech stocks. As a sector that, while not immune to broader pressures, generally manages to
Under the Microscope: 3 Biotech Stocks Pioneering Tomorrow's Cures
04:43pm, Thursday, 09'th Nov 2023
In the fluctuating U.S. stock market, biotech stocks have faced challenges. The sector's most popular index, iShares Biotechnology ETF (NASDAQ: IBB ), is dropping 9% year to date (YTD).
3 Promising Biotech Stocks Flying Under the Radar
05:19am, Wednesday, 08'th Nov 2023
Thanks to the biotechnology sector, the advances and improvement of processes within the health sector have been incredible. The impact with society and the contribution they make both directly and in
Halozyme (HALO) Q3 Earnings Top Estimates, Revenues Lag
12:47pm, Tuesday, 07'th Nov 2023
Halozyme's (HALO) third-quarter earnings beat estimates, while revenues miss the same. The company maintains revenue guidance for full-year 2023.
